All News

Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.

Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.

Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.

Cody Parsons, PharmD, APh, BCCCP, explains how the AHA's 40-hospital collaborative is mapping care gaps for patients with HFpEF and HFmrEF.

Erica Marini recaps October’s neurology pharmacy news, from FDA updates and new multiple sclerosis trial data to a fatal epilepsy case that shows the danger of patients relying on AI for medication advice.

Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.

Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.

Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.

At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.

ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.

Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.

Multidisciplinary institutional guidelines, more education and advocacy from pharmacists, national consensus guidance, and clinical trials that use the newer equations are needed in the hematology/oncology space.

Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.

The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.

The panelists recommend cross-comparing equations, deciding doses with the care team, and watching for patients at high risk of inaccurate estimates when moving chemotherapy dosing from Cockcroft-Gault to eGFR.

Kristen Hartzell, PharmD, explains that long-term care pharmacies can counter vaccine fatigue and raise influenza vaccination rates among older adults.

Moving from Cockcroft-Gault to race-agnostic estimated glomerular filtration rate (eGFR) for drug dosing is slowed by older trial data, inconsistent package inserts, gaps in education, and the work of updating EHR order sets.

Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.

A pharmacy technician reflects on 3 patient encounters that reshaped his understanding of what a real patient requires.

C difficile survivor Caitlin McClain discusses the Peggy Lillis Foundation’s patient support and policy work, the need for new antibiotics and stronger stewardship, and the lasting psychological impact of the disease.

C difficile survivor Caitlin McClain describes how pharmacists helped secure her fidaxomicin supply and guide her recovery.

Brooke Hudspeth, PharmD, explains why community pharmacists, often the source of meters and supplies, are well positioned to guide new testers.

Convenience should not replace connection.

Treated patients also had fewer postacute hospitalizations and deaths, but individuals without risk factors saw no benefit.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.

Pharmacists have shown they can safely do more for patients. Now regulation and reimbursement have to catch up.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.